NASDAQ: RAPP
Rapport Therapeutics Inc Stock Ownership - Who owns Rapport Therapeutics?

Insider buying vs selling

Have Rapport Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Abraham CeesayCEO2026-07-277$42.74
$299.15Sell
Abraham CeesayCEO2026-07-272,203$42.11
$92.76kSell
Abraham CeesayCEO2026-07-145,481$39.72
$217.72kSell
Abraham CeesayCEO2026-07-142,729$40.57
$110.72kSell
Cheryl GaultChief Operating Officer2026-06-303,308$42.17
$139.50kSell
Cheryl GaultChief Operating Officer2026-06-301,900$40.09
$76.17kSell
Cheryl GaultChief Operating Officer2026-06-303,792$41.39
$156.96kSell
Cheryl GaultChief Operating Officer2026-06-301,000$43.16
$43.16kSell
Abraham CeesayChief Executive Officer2026-06-29876$40.34
$35.34kSell
Abraham CeesayChief Executive Officer2026-06-297,344$39.77
$292.06kSell

1 of 8

RAPP insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when RAPP insiders and whales buy or sell their stock.

RAPP Shareholders

What type of owners hold Rapport Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Third Rock Ventures V LP15.16%7,249,743$297.09MInsider
Fmr LLC14.99%7,168,939$293.78MInstitution
Trv GP V LLC14.92%7,135,233$292.40MInstitution
Arch Venture Management LLC7.80%3,728,738$152.80MInstitution
Arch Venture Partners XII LLC7.80%3,728,738$152.80MInsider
Capital International Investors6.48%3,097,973$126.95MInstitution
Cormorant Asset Management LP6.18%2,957,521$121.20MInstitution
Goldman Sachs Group Inc 16.15%2,942,251$120.57MInstitution
Blackrock Inc5.24%2,505,955$102.69MInstitution
James Healy4.17%1,995,594$81.78MInsider

1 of 3

RAPP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RAPP77.47%22.53%Net SellingNet Selling
ZBIO74.49%25.51%Net BuyingNet Buying
IOVA19.87%80.13%Net SellingNet Selling
VRDN75.63%24.37%Net BuyingNet Buying
TYRA65.84%34.16%Net Selling

Rapport Therapeutics Stock Ownership FAQ

Who owns Rapport Therapeutics?

Rapport Therapeutics (NASDAQ: RAPP) is owned by 109.74% institutional shareholders, 31.91% Rapport Therapeutics insiders, and 0.00% retail investors. Third Rock Ventures V LP is the largest individual Rapport Therapeutics shareholder, owning 7.25M shares representing 15.16% of the company. Third Rock Ventures V LP's Rapport Therapeutics shares are currently valued at $295.72M.

If you're new to stock investing, here's how to buy Rapport Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.